Dear Readers,

ovarian cancer is still one of the most common malignant tumors among women. It should be noted that some of the highest incidence and mortality rates due to this disease occur in the countries of Central and Eastern Europe. Therefore, it is so important to search for effective anticancer treatment methods in this patients. In the latest issue of “OncoReview”, Poboży et al., in an elegant review, present the current state of knowledge about the poly-ADP-ribose polymerase inhibitor olaparib, which is a representative of modern drugs that are another option for the treatment of ovarian cancer.

In turn, Jakub Żołnierek from the Polish Kidney Cancer Group presents modern therapeutic options using molecularly targeted drugs and next generation of cancer immunotherapy in the first-line treatment in patients with advanced renal cell carcinoma, which are available in Poland in programs financed by the National Health Fund.

E2F transcription factor 2 (E2F2) protein is the transcription factor which regulates the expression of a number of genes important in cell proliferation and playing an important role in tumorigenesis. In their review, Domańska et al. present current research results that confirm the importance of E2F2 in tumor growth, progression, metastasis and anticancer drug resistance in such cancers as breast, colon, gastric, laryngeal, liver, lung, ovarian, pancreatic, and prostate. Further research on E2F2 pathways may translate into the discovery of novel pharmacological anti-cancer treatments in the future.

With best wishes for an inspiring reading.

EDITOR-IN-CHIEF (Europe)
Radosław Grabysa, MD, PhD, Associate Professor